Dr. DiGiovanna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
Yale Physicians Building 2ND floor
New Haven, CT 06519Phone+1 203-688-4191Fax+1 203-737-2617
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1997- Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1993
Yale School of MedicineClass of 1990
Certifications & Licensure
CT State Medical License 1993 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
Publications & Presentations
PubMed
- 1392 citationsTrastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas
The New England Journal of Medicine. 2019-02-14 - 58 citationsSynergistic interactions between tamoxifen and trastuzumab (Herceptin)Athanassios Argiris, Chun Xia Wang, Steve G. Whalen, Michael P. DiGiovanna
Clinical Cancer Research. 2004-02-15 - 182 citationsRelationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer PatientsMichael P. DiGiovanna, David F. Stern, Susan M. Edgerton, Steve G. Whalen, Dan H. Moore
Journal of Clinical Oncology. 2005-02-20
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
